{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chan WL"],"funding":["Pfizer (United Kingdom)"],"pagination":["4084"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11639799"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(23)"],"pubmed_abstract":["<b>Background</b>: Breast cancer survivors often face physical and psychological challenges, including weight gain, metabolic syndrome, and reduced quality of life. To address these concerns, a mobile app-based rehabilitation program called \"THRIVE\" was developed to improve physical activity, medication adherence, and health-related quality of life (HRQoL) in this population. <b>Methods</b>: This prospective, single-arm study assessed the feasibility and effectiveness of the \"THRIVE\" app among breast cancer survivors undergoing hormonal therapy. Participants were recruited from Queen Mary Hospital in Hong Kong between December 2022 and June 2023. Eligible survivors had completed treatment within the last five years or had stable advanced disease on hormonal therapy. Participants monitored "],"journal":["Cancers"],"pubmed_title":["Digital Rehabilitation Program for Breast Cancer Survivors on Adjuvant Hormonal Therapy: A Feasibility Study."],"pmcid":["PMC11639799"],"funding_grant_id":["60555419"],"pubmed_authors":["Chan WL","Lam WW","Kwong D","Liu M","Zhang Y","Wong YL","Yun B","Hou HL","Lee VH","Tai YL"],"additional_accession":[]},"is_claimable":false,"name":"Digital Rehabilitation Program for Breast Cancer Survivors on Adjuvant Hormonal Therapy: A Feasibility Study.","description":"<b>Background</b>: Breast cancer survivors often face physical and psychological challenges, including weight gain, metabolic syndrome, and reduced quality of life. To address these concerns, a mobile app-based rehabilitation program called \"THRIVE\" was developed to improve physical activity, medication adherence, and health-related quality of life (HRQoL) in this population. <b>Methods</b>: This prospective, single-arm study assessed the feasibility and effectiveness of the \"THRIVE\" app among breast cancer survivors undergoing hormonal therapy. Participants were recruited from Queen Mary Hospital in Hong Kong between December 2022 and June 2023. Eligible survivors had completed treatment within the last five years or had stable advanced disease on hormonal therapy. Participants monitored ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T02:14:18.95Z","creation":"2025-04-04T02:14:18.95Z"},"accession":"S-EPMC11639799","cross_references":{"pubmed":["39682269"],"doi":["10.3390/cancers16234084"]}}